小青龙颗粒联合布地奈德治疗支气管哮喘急性发作期的临床研究
|
摘要
目的探讨小青龙颗粒联合布地奈德气雾剂治疗支气管哮喘急性发作期的临床疗效。方法选取2016年2月—2018年2月澄迈县人民医院收治的支气管哮喘急性发作期患者132例为研究对象,根据随机数字表法将患者分为对照组和治疗组,每组各66例。对照组患者雾化吸入布地奈德气雾剂,2揿/次,2～4次/d;治疗组在对照组治疗的基础上口服小青龙颗粒,1袋/次,3次/d。两组患者均连续用药7d。观察两组的临床疗效,比较两组的临床症状消失时间、肺功能指标、血清炎性因子。结果治疗后,对照组和治疗组的总有效率分别为83.3%、92.4%,两组比较差异有统计学意义(P<0.05)。治疗后,治疗组咳嗽、气喘、湿啰音、哮鸣音消失时间均显著短于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组PEV1、PEF、FVC、PEV1/FVC均显著升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组肺功能指标明显高于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组血清IL-17、IL-35、HMGB1水平均明显下降,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组血清炎性因子水平明显低于对照组,两组比较差异有统计学意义(P<0.05)。结论小青龙颗粒联合布地奈德气雾剂治疗支气管哮喘急性发作期具有较好的临床疗效,可缓解临床症状,改善肺功能,降低炎症反应,具有一定的临床推广应用价值。
Objective To investigate the clinical effect of Xiaoqinglong Granules combined with Budesonide Inhalation Aerosol in treatment of acute attack of bronchial asthma. Methods Patients(132 cases) with acute attack of bronchial asthma in Chengmai County People's Hospital from February 2016 to February 2018 were randomly divided into control and treatment groups, and each group had 66 cases. Patients in the control group were atomization inhalation administered with Budesonide Inhalation Aerosol, 2 presses/time, 2 — 4 times daily. Patients in the treatment group were po administered with Xiaoqinglong Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 2 d. After treatment, the clinical efficacies were evaluated, and the disappearing time of clinical symptoms, lung function indexes, and serum inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.3% and 92.4%, respectively, and there was difference between two groups(P < 0.05). After treatment, the disappearing times of cough, asthma, moist rale and wheezing in the treatment group were significantly shorter than those in the control group, and there was difference between two groups(P < 0.05). After treatment, PEV1, PEF, FVC, and PEV1/FVC in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And the lung function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of IL-17, IL-35, and HMGB1 in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the serum inflammatory factors indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Xiaoqinglong Granules combined with Budesonide Inhalation Aerosol has clinical curative effect in treatment of acute attack of bronchial asthma, can relieve clinical symptoms, improve pulmonary function, and reduce inflammatory response, which has a certain clinical application value.
Objective To investigate the clinical effect of Xiaoqinglong Granules combined with Budesonide Inhalation Aerosol in treatment of acute attack of bronchial asthma. Methods Patients(132 cases) with acute attack of bronchial asthma in Chengmai County People's Hospital from February 2016 to February 2018 were randomly divided into control and treatment groups, and each group had 66 cases. Patients in the control group were atomization inhalation administered with Budesonide Inhalation Aerosol, 2 presses/time, 2 — 4 times daily. Patients in the treatment group were po administered with Xiaoqinglong Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 2 d. After treatment, the clinical efficacies were evaluated, and the disappearing time of clinical symptoms, lung function indexes, and serum inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.3% and 92.4%, respectively, and there was difference between two groups(P < 0.05). After treatment, the disappearing times of cough, asthma, moist rale and wheezing in the treatment group were significantly shorter than those in the control group, and there was difference between two groups(P < 0.05). After treatment, PEV1, PEF, FVC, and PEV1/FVC in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And the lung function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of IL-17, IL-35, and HMGB1 in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the serum inflammatory factors indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Xiaoqinglong Granules combined with Budesonide Inhalation Aerosol has clinical curative effect in treatment of acute attack of bronchial asthma, can relieve clinical symptoms, improve pulmonary function, and reduce inflammatory response, which has a certain clinical application value.
引文
[1]北京协和医院.呼吸内科诊疗常规[M].北京:人民卫生出版社, 2004:314.
[2]尚云飞,朱立成.小青龙颗粒治疗支气管哮喘急性发作的临床观察[J].现代中西医结合杂志,2012,21(8):799-800.
[3]徐敏洁,宋丽萍.布地奈德治疗中重度支气管哮喘急性发作患儿的效果及对肺功能的影响[J].中国医院药学杂志, 2014, 34(7):565-568.
[4]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(2016年版)[J].中华结核和呼吸杂志, 2016, 39(9):675-697.
[5]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社, 2002:61-65.
[6]吴迪.支气管哮喘治疗现状及进展[J].医学综述,2013, 19(4):664-667.
[7]蔡高翔,苏冬菊,李彬斐.多索茶碱联合布地奈德雾化吸入治疗对支气管哮喘急性发作的疗效观察[J].哈尔滨医科大学学报, 2015, 49(2):149-152.
[8]刘丽芬.雾化吸入布地奈德与沙丁胺醇治疗支气管哮喘急性发作对HMGB1的影响及治疗效果评价[J].临床肺科杂志, 2016, 21(5):805-808.
[9]王世聪,黄河清,李希.小青龙汤治疗支气管哮喘研究进展[J].福建中医学院学报, 2009, 19(2):71-72.
[10]朱立成,尚云飞,姜水菊.小青龙颗粒对支气管哮喘患者外周血Th17/Treg平衡影响的研究[J].现代中西医结合杂志, 2012, 21(20):2173-2174.
[11]姜水菊,沈水杰,尚云飞.小青龙颗粒联合沙美特罗氟替卡松治疗支气管哮喘急性发作的临床观察[J].现代中西医结合杂志, 2016, 25(5):499-500.
[12]沈红燕,杨丽萍,杨芳.支气管哮喘儿童血清IL-17、IL-35水平与肺功能的相关性分析[J].中国妇幼保健,2017, 32(20):5002-5004.
[13]阎敏娜,项保利,张素贞,等.支气管哮喘患儿IL-17及IL-35水平变化及意义[J].临床儿科杂志,2018,36(4):268-271.
[14]熊泽忠,梁大胜.高迁移率族蛋白B1在支气管哮喘中的研究进展[J].国际呼吸杂志, 2018,38(2):122-124.
[2]尚云飞,朱立成.小青龙颗粒治疗支气管哮喘急性发作的临床观察[J].现代中西医结合杂志,2012,21(8):799-800.
[3]徐敏洁,宋丽萍.布地奈德治疗中重度支气管哮喘急性发作患儿的效果及对肺功能的影响[J].中国医院药学杂志, 2014, 34(7):565-568.
[4]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(2016年版)[J].中华结核和呼吸杂志, 2016, 39(9):675-697.
[5]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社, 2002:61-65.
[6]吴迪.支气管哮喘治疗现状及进展[J].医学综述,2013, 19(4):664-667.
[7]蔡高翔,苏冬菊,李彬斐.多索茶碱联合布地奈德雾化吸入治疗对支气管哮喘急性发作的疗效观察[J].哈尔滨医科大学学报, 2015, 49(2):149-152.
[8]刘丽芬.雾化吸入布地奈德与沙丁胺醇治疗支气管哮喘急性发作对HMGB1的影响及治疗效果评价[J].临床肺科杂志, 2016, 21(5):805-808.
[9]王世聪,黄河清,李希.小青龙汤治疗支气管哮喘研究进展[J].福建中医学院学报, 2009, 19(2):71-72.
[10]朱立成,尚云飞,姜水菊.小青龙颗粒对支气管哮喘患者外周血Th17/Treg平衡影响的研究[J].现代中西医结合杂志, 2012, 21(20):2173-2174.
[11]姜水菊,沈水杰,尚云飞.小青龙颗粒联合沙美特罗氟替卡松治疗支气管哮喘急性发作的临床观察[J].现代中西医结合杂志, 2016, 25(5):499-500.
[12]沈红燕,杨丽萍,杨芳.支气管哮喘儿童血清IL-17、IL-35水平与肺功能的相关性分析[J].中国妇幼保健,2017, 32(20):5002-5004.
[13]阎敏娜,项保利,张素贞,等.支气管哮喘患儿IL-17及IL-35水平变化及意义[J].临床儿科杂志,2018,36(4):268-271.
[14]熊泽忠,梁大胜.高迁移率族蛋白B1在支气管哮喘中的研究进展[J].国际呼吸杂志, 2018,38(2):122-124.